Recruiting

OssiMend BA

Sponsor:

Collagen Matrix

Code:

NCT04775537

Conditions

Spinal Disease

Degenerative Disc Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

OssiMend™ Bioactive Moldable

Study Details

Brief summary:

The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material

Conditions

Spinal Disease

Degenerative Disc Disease

Study ID

NCT04775537

Start date

Jan 21, 2021

Status verified date

Jan, 2025

Completion date

Jan 30, 2027

Anticipated

Primary completion date

Dec 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Subject must be 18 years of age or older at the time of consent and must have a documented diagnosis of degenerative disc disease (DDD) that has failed to respond to nonoperative treatment for at least 6 months. DDD is defined by back and/or radicular pain with degeneration of the disc as confirmed by medical history, physical examination, and radiographic studies that may include CT, MRI, plain X-ray film, discography, myelography, etc. with one or more of the following findings:

  • Instability as defined by >3mm translation or >5 degrees angulation
  • Osteophyte formation of facet joints or vertebral endplates
  • Decreased disc height, on average by >2mm, but dependent upon the spinal level
  • Herniated nucleus pulposus
  • Facet joint degeneration/changes

Exclusion Criteria:

1. Subject is under 18 years of age at the time of consent
2. Subject has had prior lumbar spine fusion surgery at any level
3. Subject is currently undergoing treatment for malignancy or has undergone treatment for malignancy
4. Subject is pregnant or nursing or planning to become pregnant during the two years (24 months) following arthrodesis
5. Subject has an active (local or systemic) infection or is undergoing adjunctive treatment for infection
6. Subjects under workers compensation or active litigation

Study Design

Enrollment

120 participants

Anticipated

Interventions and Outcome Measures

Arms

OssiMend™ Bioactive Moldable

Patients undergoing Lumber Spine Fusion

Interventions

OssiMend™ Bioactive Moldable

Lumbar Spine fusion with OssiMend™ Bioactive Moldable

Primary outcome measure

  • Fusion Success [ Time Frame: 12 months ]

Central Contacts and Locations

Locations

Hartford Hospital

Recruiting

Hartford, Connecticut, United States, 06102

Contacts

Principal Investigator:

Pedro Coutinho, MD

More Information

Sponsor

Collagen Matrix

Last update posted

Oct 16, 2025

Last verified

Jan, 2025

Keywords

  • Bone Graft
  • Lumbar Fusion

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Collagen Matrix on 2025-10-16.